Ricc A/S

17 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Roche Innovation Center Copenhagen A/S (to 2025)

Ending by 2030

Dec 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 2, 2026
The maintenance fee for Amino-LNA, thio-LNA and alpha-L-oxy-LN (US 9,045,518) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
1 fee due Jan 23, 2027
The maintenance fee for Poly Oligomer Compound with Biocleavable Conjugates (US 10,358,643) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
3 fees due Feb 6 to 28, 2027 · next Feb 6
2 fees due Apr 15 to 22, 2027 · next Apr 15

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,653,252	Short interfering RNA (siRNA) analogues In force Term ends Dec 31, 2027 · From the USPTO record	In force	Term ends Dec 31, 2027	From the USPTO record
US 9,045,518	Amino-LNA, thio-LNA and alpha-L-oxy-LN In force Term ends Apr 5, 2028 · From the USPTO record	In force	Term ends Apr 5, 2028	From the USPTO record
US 9,790,493	MICROMIRs In force Term ends Oct 3, 2028 · From the USPTO record	In force	Term ends Oct 3, 2028	From the USPTO record
US 10,450,564	Micromirs In force Ends no later than Oct 3, 2028 · From the USPTO record	In force	Ends no later than Oct 3, 2028	From the USPTO record
US 8,288,356	MicroRNAs In force Term ends Sep 28, 2029 · From the USPTO record	In force	Term ends Sep 28, 2029	From the USPTO record
US 8,563,528	Antisense oligomers targeting PCSK9 In force Term ends Oct 30, 2030 · From the USPTO record	In force	Term ends Oct 30, 2030	From the USPTO record
US 8,906,871	MicromiRs In force Term ends Aug 5, 2031 · From the USPTO record	In force	Term ends Aug 5, 2031	From the USPTO record
US 10,077,443	Oligonucleotide conjugates In force Term ends Nov 14, 2033 · From the USPTO record	In force	Term ends Nov 14, 2033	From the USPTO record
US 9,879,265	Oligonucleotide conjugates In force Term ends Jun 27, 2034 · From the USPTO record	In force	Term ends Jun 27, 2034	From the USPTO record
US 10,370,668	Manufacture of antisense oligomers and conjugates targeting PCSK9 In force Term ends Jun 27, 2034 · From the USPTO record	In force	Term ends Jun 27, 2034	From the USPTO record

10 of 17 patents shown.

Pro members see all 17.

Pro members: see all 17 patents

Also on record, not counted in the 17: 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro